Lexicon Pharmaceuticals Inc.'s diabetes drug Zynquista beat placebo and matched Eli Lilly and Co.'s Jardiance in reducing blood sugar levels of certain patients with type 2 diabetes in a late-stage study.
The Sota-Empa multicenter study compared the effectiveness of Zynquista, placebo and empagliflozin, sold by Lilly and Boehringer Ingelheim GmbH under brand name Jardiance, on 700 patients over a 26 week period.
Patients in the study had inadequate sugar metabolism from type 2 diabetes, despite using a class of oral drugs known as Dipeptidyl peptidase-4 inhibitors, which help preserve a group of hormones that decrease glucose levels in the blood.
The company expects top-line results from its remaining late-stage studies of Zynquista in early 2020, Lexicon's executive vice president and chief medical officer, Pablo Lapuerta, said in a statement.
Zynquista, or sotagliflozin, was approved by the European Commission in April as an add-on therapy for adults with type 1 diabetes. In contrast, the U.S Food and Drug Administration rejected it for the same treatment and denied the Woodlands, Texas-based company's appeal over the rejection.